Skip to main content

Table 1 Cutoffs for greater or lesser clinical or functional response

From: Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy

  Greater response Lesser response
Clinical
 CDAI [10] Remission (≤ 2.8) or LDA (> 2.8 to ≤ 10)
TA remission/LDA (≤ 10)
Moderate/high disease activity (> 10)
TA moderate/high disease activity (> 10)
 %∆CDAI [11]  ≥ 85% decrease Increase, or < 85% decrease
 ACR-N [11]  ≥ ACR70  < ACR70
Functional
 ∆HAQ-DI [14] Decrease ≥ 0.22 (MCID) Increase, or decrease < 0.22 (non-MCID)
 HAQ-DI [12, 13] Normalized (< 0.5) Not normalized (≥ 0.5)
  1. , change from baseline; ACR70, American College of Rheumatology ≥ 70% response rate; ACR-N, American College of Rheumatology response rate, where ACR is the percentage improvement from baseline in American College of Rheumatology components, and N represents the minimum percentage achieved by each patient; CDAI, Clinical Disease Activity Index; HAQ-DI, Health Assessment Questionnaire-Disability Index; LDA, low disease activity; MCID, minimum clinically important difference; TA, time-averaged